Brought to you by 
Isis' financing vehicle supports CV/metabolic development
24 Jun 2020
Executive Summary
In a deal expected to last four years, antisense drug developer Isis Pharmaceuticals has licensed intellectual property related to its cholesterol candidate ISIS301012 and two diabetes programs to Symphony GenIsis, an off-balance sheet entity that was formed by a $75mm investment from private equity company Symphony Capital and other co-investors.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Special-Purpose Financing Vehicle
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Isis' financing vehicle supports CV/metabolic development
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice